Xing Jiazhen, Zhang Xiaoqing, Fan Junwei, Shen Bin, Men Tongyi, Wang Jianning
Department of Urology Surgery, Shandong Qianfoshan Hospital, School of Medicine, Taishan Medical College, Shandong, China.
Eur J Clin Pharmacol. 2015 Feb;71(2):191-8. doi: 10.1007/s00228-014-1785-8. Epub 2014 Dec 10.
Interleukin 18 (IL-18) is a potent proinflammatory cytokine thought to down-regulate cytochrome P450 (CYP) enzyme activities. This study aimed to assess the potential influence of two functional single nucleotide polymorphisms (SNPs) in the IL-18 promoter region on the tacrolimus pharmacokinetics in Chinese renal transplant patients.
We enrolled 96 renal allograft recipients receiving tacrolimus-based immunosuppressive regiments. Two functional SNPs in the IL-18 gene promoter region at the positions -137G/C (rs187283) and -607A/C (rs1946518) and one SNP (rs776746) of CYP3A5 were genotyped using a Mass ARRAY platform. Tacrolimus daily doses (mg/day) and trough tacrolimus concentration (ng/ml) were continuously recorded for 1 month after transplantation.
The tacrolimus C/D ratio was significantly associated with the IL-18 rs1946518 gene polymorphism in the first month after transplantation (P = 0.0225). We studied the influence of its polymorphism on tacrolimus C/D ratios in subjects with different CYP3A5 genotype backgrounds, and among patients with CYP3A5 expressers, the difference among the three genotypes was even more striking (P < 0.001). We did not find significant differences in tacrolimus C/D ratios between the IL-18 rs187238 genotypes, either nominally or according to the CYP3A5 genotype. In a simple linear regression model, age, hemoglobin (Hb), CYP3A5 gene polymorphisms, and IL-18 A-607C gene polymorphisms were associated with log-transformed tacrolimus C/D ratios (P < 0.05). In the final multiple linear regression model, CYP3A5 polymorphisms were the most important variant, accounting for 19.5 % of total variation involved in tacrolimus pharmacokinetics.
Our findings suggest that a combined analysis of CYP3A5 and IL-18 promoter polymorphisms may help clinicians develop individualized tacrolimus treatment, which is based on determining CYP3A5 genotype.
白细胞介素18(IL-18)是一种强有力的促炎细胞因子,被认为可下调细胞色素P450(CYP)酶的活性。本研究旨在评估IL-18启动子区域两个功能性单核苷酸多态性(SNP)对中国肾移植患者他克莫司药代动力学的潜在影响。
我们纳入了96名接受以他克莫司为基础的免疫抑制方案的肾移植受者。使用Mass ARRAY平台对IL-18基因启动子区域位于-137G/C(rs187283)和-607A/C(rs1946518)位置的两个功能性SNP以及CYP3A5的一个SNP(rs776746)进行基因分型。移植后连续1个月记录他克莫司的每日剂量(mg/天)和他克莫司谷浓度(ng/ml)。
移植后第一个月,他克莫司的C/D比值与IL-18 rs1946518基因多态性显著相关(P = 0.0225)。我们研究了其多态性对不同CYP3A5基因型背景受试者他克莫司C/D比值的影响,在CYP3A5表达者患者中,三种基因型之间的差异更为显著(P < 0.001)。无论是名义上还是根据CYP3A5基因型,我们均未发现IL-18 rs187238基因型之间他克莫司C/D比值存在显著差异。在一个简单线性回归模型中,年龄、血红蛋白(Hb)、CYP3A5基因多态性和IL-18 A-607C基因多态性与经对数转换的他克莫司C/D比值相关(P < 0.05)。在最终的多元线性回归模型中,CYP3A5多态性是最重要的变量,占他克莫司药代动力学总变异的19.5%。
我们的研究结果表明,对CYP3A5和IL-18启动子多态性进行联合分析可能有助于临床医生制定基于CYP3A5基因型测定的个体化他克莫司治疗方案。